TABLE 1.
Patient Demographics and Baseline Characteristics
| Characteristic | Prior CTN SR 200 mg (n = 156) |
Prior CTN SR 400 mg (n = 151) |
Prior Placebo (n = 187) |
De Novo (n = 168) |
Total (N = 662) |
|---|---|---|---|---|---|
| Age (y),* mean (SD) | 36.9 (10.2) | 37.2 (10.7) | 36.0 (9.8) | 36.8 (9.7) | 36.7 (10.1) |
| Sex,* n (%) | |||||
| Male | 80 (51.3) | 75 (49.7) | 93 (49.7) | 75 (44.6) | 323 (48.8) |
| Female | 76 (48.7) | 76 (50.3) | 94 (50.3) | 92 (54.8) | 338 (51.1) |
| Race,* n (%) | |||||
| White | 121 (77.6) | 122 (80.8) | 162 (86.6) | 144 (85.7) | 549 (82.9) |
| Black | 19 (12.2) | 21 (13.9) | 16 (8.6) | 10 (6.0) | 66 (10.0) |
| Asian | 7 (4.5) | 1 (0.7) | 6 (3.2) | 9 (5.4) | 23 (3.5) |
| American Indian or Alaska Native | 0 | 2 (1.3) | 1 (0.5) | 1 (0.6) | 4 (0.6) |
| Native Hawaiian or Other Pacific Islander | 1 (0.6) | 0 | 0 | 0 | 1 (0.2) |
| Other | 8 (5.1) | 5 (3.3) | 2 (1.1) | 3 (1.8) | 18 (2.7) |
| Ethnicity,* n (%) | |||||
| Hispanic or Latino | 34 (21.8) | 36 (23.8) | 35 (18.7) | 50 (29.8) | 155 (23.4) |
| BMI (kg/m2), mean (SD) | 29.1 (7.3) | 29.1 (6.4) | 28.5 (7.8) | 28.6 (5.0) | 28.8 (6.7) |
| AISRS score, mean (SD) | 32.6 (10.8) | 32.6 (11.2) | 34.9 (10.2) | 37.1 (8.5) | 34.4 (10.3) |
*
n = 661.
AISRS indicates Adult ADHD Investigator Symptom Rating Scale; BMI, body mass index; CTN SR, centanafadine sustained release.